Advertisement

JID VisualDx Quiz: January 2015

      QUESTIONS

      • 1.
        What is your diagnosis?
        • a.
          Bullous pemphigoid.
        • b.
          Urticaria.
        • c.
          Subacute cutaneous lupus.
        • d.
          Erythema multiforme.
        • e.
          Urticaria pigmentosa.
      • 2.
        How does the ASTERIA I study differ from previous studies of omalizumab for chronic idiopathic urticaria?
        • a.
          Dosing of the drug.
        • b.
          Inclusion criteria.
        • c.
          Duration of the study.
        • d.
          Ability to use additional concurrent drugs.
        • e.
          All of the above.
      • 3.
        From the results of this study, which of the following is true regarding omalizumab for chronic idiopathic urticaria (CIU) (choose all that apply)?
        • a.
          Improves CIU in a dose-dependent fashion.
        • b.
          Most clinical improvement is experienced soon after initiation.
        • c.
          Maximal benefit was demonstrated with this study.
        • d.
          Placebo effect is most persistent of all treatments.
        • e.
          All of the above.

      TOPIC ARTICLE

      Questions 2 and 3 refer to the following article:
      Answers are available as supplementary material at http://dx.doi.org/10.1038/jid.2014.473.

      Appendix

      References

        • Saini S.S.
        • Bindslev-Jensen C.
        • Maurer M.
        • et al.
        Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
        J Invest Dermatol. 2015; 135: 67-75